GUARDANT HEALTH CL. A Logo
US40131M1099
A2N5RY
GH

GUARDANT HEALTH CL. A

Loading quotes...

Forecast

The analysts' average price target is €185.53 (+40.11%). The median is €182.43 (+37.77%).

Buy
  30
Hold
  0
Sell
  1

Discussions in the community

  • Translated from German

    Unable to add stock

    kajdo kajdo I in Schnack

    0 12

  • Guardant Health reports record quarter, raises full-year guidance and stock nears all-time high

    Guardant Health reported a record quarter with revenue up 44% to $335 million and raised its full-year guidance to $1.34–$1.36 billion. Growth was driven by core oncology revenues and the expanding Shield colorectal screening program, while a new lab process is expected to cut the cost per Shield test by about 15% by year-end. The company aims for cash-flow breakeven by the end of 2027; in the near term it remains loss-making with an expected cash burn of roughly $200 million in 2026. Chart‑wise, the stock broke out of a sideways consolidation and is trading just below its previous all-time high. » More on finanzen.net


  • Guardant Health: Shield screening scales strongly, CDx business gains from new approvals

    Guardant Health said at the Morgan Stanley conference it posted more than 40% revenue growth in Q2, an oncology volume increase of over 60% and Shield growth of more than 250%. According to management, Shield covers 80% of eligible individuals (about 94 million people) and cost per test is expected to fall from just over $400 to roughly $350 by year-end, with a long-term target of $200. Guardant360 Liquid CDx received an expanded FDA approval as the sole companion diagnostic for Camizestrant; the company expects ADLT status for Guardant360 in H1 2025 and sees further growth potential from combined screening, profiling and MRD applications despite near-term pricing and reimbursement pressure. » More on de.investing.com


  • Guardant Health: EviCore to reimburse Shield blood test for colorectal cancer screening starting 2027

    Guardant Health announced that EviCore by Evernorth has added the Shield blood test for colorectal cancer early detection to its clinical guidelines effective January 1, 2027. Reimbursement will apply to insured individuals aged 45 and older at average risk, expanding the covered population to about 94 million people across 23 states. Shield is FDA-cleared for primary screening using methylation partitioning cell-free DNA technology; a positive result requires follow-up colonoscopy. The test is included in American Cancer Society and National Comprehensive Cancer Network guidelines and has already been used more than 200,000 times. » More on de.investing.com


  • Guardant Health scales Shield blood test for colorectal cancer and expands market opportunities

    Guardant Health's FDA-approved and reimbursed Shield blood test provides a painless method for colorectal cancer screening and opens up a mass market. Despite ongoing spending on sales and research, rising test volumes, falling lab costs and partnerships with pharma companies are driving scale-up. The company plans to gradually extend the offering to additional cancer types. » More on finanzen.net


  • Artisan adds Guardant Health, cites leadership in liquid biopsies and rising Shield adoption

    Artisan Mid Cap Fund added Guardant Health during Q2 2026, highlighting the company's market-leading liquid biopsy diagnostics and expanding portfolio across oncology and cancer screening. Guardant reported another strong quarter driven by higher testing volumes and accelerating adoption of its Shield colorectal screening test, prompting management to raise full-year revenue guidance. The fund believes Guardant is well positioned to benefit from growing precision oncology adoption, AI-enabled diagnostics, an expanding data repository and improving reimbursement and product catalysts. » More on finance.yahoo.com

Historical dividends Dividends

All dividend metrics All metrics
In 2022, GUARDANT HEALTH CL. A has already paid €0.11 in dividends. The last payout was in June 2022.

Financials

In the last quarter, GUARDANT HEALTH CL. A had revenue of €318.69m and net profit of -€109.79m
(EUR) September 2026
YoY
Revenue 318.69m 41.02%
Gross profit 208.49m 42.57%
Net profit -109.79m 38.95%
EBITDA -99.32m 41.72%

Fundamentals

Metric Value
Market capitalization
€17.91bn
Number of shares
135.29m
52-week high/low
€174.27 - €68.00
Dividends No
Beta
1.66
P/E ratio
-39.44
PEG ratio
2.98
P/B ratio
-70.71
P/S ratio
15.35

Company profile

Guardant Health, Inc., a precision oncology company, provides blood tests, data sets, and analytics in the United States and internationally. The company offers Guardant360, Guardant360 LDT, Guardant360 CDx, and GuardantOMNI liquid biopsy-based tests for advanced stage cancer; and GuardantINFORM, an in-silico research platform that comprise a clinical-genomic liquid biopsy dataset of advanced cancer patients. It is also developing LUNAR-2 test for the early detection of colorectal cancer in asymptomatic individuals eligible; and GuardantConnect, an integrated software-based solution for clinical and biopharmaceutical customers seeking to connect patients tested with the Guardant360 assay with actionable alterations with potentially relevant clinical trials. In addition, the company offers Guardant Reveal Test for neoadjuvant and adjuvant treatment selection in early-stage cancer patients; Guardant360 tissue genotyping product; and Guardant-19 for use in the detection of the novel coronavirus. Further, it offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, and kits fulfillment related services to biopharmaceutical companies and medical institutions. The company was incorporated in 2011 and is headquartered in Redwood City, California.

Name
GUARDANT HEALTH CL. A
CEO
Helmy Eltoukhy
Headquarters Palo Alto, ca
USA
Website
Sector
Health Care
Industry
Health Care Equipment & Supplies
IPO
04/10/2018
Employees 2,498

Ticker symbols

Exchange Symbol
NASDAQ
GH
Frankfurt
5GH.F
DĂĽsseldorf
5GH.DU
MĂĽnchen
5GH.MU
🍪

Parqet  uses cookies. Learn more